JP2018530564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530564A5 JP2018530564A5 JP2018517841A JP2018517841A JP2018530564A5 JP 2018530564 A5 JP2018530564 A5 JP 2018530564A5 JP 2018517841 A JP2018517841 A JP 2018517841A JP 2018517841 A JP2018517841 A JP 2018517841A JP 2018530564 A5 JP2018530564 A5 JP 2018530564A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- sur1
- administered
- injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940125400 channel inhibitor Drugs 0.000 claims description 61
- 238000001802 infusion Methods 0.000 claims description 54
- 230000006378 damage Effects 0.000 claims description 48
- 208000027418 Wounds and injury Diseases 0.000 claims description 47
- 208000014674 injury Diseases 0.000 claims description 47
- 206010030113 Oedema Diseases 0.000 claims description 34
- 210000003169 central nervous system Anatomy 0.000 claims description 33
- 206010048962 Brain oedema Diseases 0.000 claims description 32
- 208000006752 brain edema Diseases 0.000 claims description 32
- 230000000926 neurological effect Effects 0.000 claims description 28
- 239000008280 blood Substances 0.000 claims description 25
- 210000004369 blood Anatomy 0.000 claims description 25
- 230000005713 exacerbation Effects 0.000 claims description 25
- 229960004580 glibenclamide Drugs 0.000 claims description 24
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical group COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 24
- 208000006011 Stroke Diseases 0.000 claims description 19
- 230000034994 death Effects 0.000 claims description 17
- 231100000517 death Toxicity 0.000 claims description 17
- 238000012360 testing method Methods 0.000 claims description 14
- 229960002277 tolazamide Drugs 0.000 claims description 14
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 claims description 14
- 210000004556 brain Anatomy 0.000 claims description 13
- 238000007428 craniotomy Methods 0.000 claims description 11
- 230000006837 decompression Effects 0.000 claims description 11
- 108091006146 Channels Proteins 0.000 claims description 9
- 206010061216 Infarction Diseases 0.000 claims description 8
- 230000007574 infarction Effects 0.000 claims description 8
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims description 7
- VFBAJFAMXTVSQA-UHFFFAOYSA-N 3-Hydroxyglibenclamide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CC(O)CCC2)C=C1 VFBAJFAMXTVSQA-UHFFFAOYSA-N 0.000 claims description 7
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 7
- 102100024645 ATP-binding cassette sub-family C member 8 Human genes 0.000 claims description 7
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims description 7
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 7
- 101000760570 Homo sapiens ATP-binding cassette sub-family C member 8 Proteins 0.000 claims description 7
- 229960001761 chlorpropamide Drugs 0.000 claims description 7
- 229960000346 gliclazide Drugs 0.000 claims description 7
- 229960004346 glimepiride Drugs 0.000 claims description 7
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 7
- 229950004994 meglitinide Drugs 0.000 claims description 7
- 239000002207 metabolite Substances 0.000 claims description 7
- -1 midaglyzol Chemical compound 0.000 claims description 7
- 229960000698 nateglinide Drugs 0.000 claims description 7
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims description 7
- 229960002354 repaglinide Drugs 0.000 claims description 7
- 230000008961 swelling Effects 0.000 claims description 7
- IUWSGCQEWOOQDN-UHFFFAOYSA-N trans-4-Hydroxyglyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(O)CC2)C=C1 IUWSGCQEWOOQDN-UHFFFAOYSA-N 0.000 claims description 7
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 6
- 230000009529 traumatic brain injury Effects 0.000 claims description 6
- 210000000278 spinal cord Anatomy 0.000 claims description 5
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 4
- 206010063036 Spinal cord oedema Diseases 0.000 claims description 4
- 210000001715 carotid artery Anatomy 0.000 claims description 4
- 230000003902 lesion Effects 0.000 claims description 4
- 210000003657 middle cerebral artery Anatomy 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 239000000902 placebo Substances 0.000 claims description 3
- 229940068196 placebo Drugs 0.000 claims description 3
- 208000010496 Heart Arrest Diseases 0.000 claims description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 2
- 206010019663 Hepatic failure Diseases 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000012790 confirmation Methods 0.000 claims description 2
- 230000001186 cumulative effect Effects 0.000 claims description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 231100000835 liver failure Toxicity 0.000 claims description 2
- 208000007903 liver failure Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 88
- 206010042674 Swelling Diseases 0.000 claims 3
- 230000006866 deterioration Effects 0.000 claims 2
- 229920000742 Cotton Polymers 0.000 claims 1
- 238000000034 method Methods 0.000 description 135
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 37
- 239000008103 glucose Substances 0.000 description 22
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 6
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 238000002597 diffusion-weighted imaging Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229940100389 Sulfonylurea Drugs 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 206010019754 Hepatitis cholestatic Diseases 0.000 description 1
- 206010023129 Jaundice cholestatic Diseases 0.000 description 1
- 201000005267 Obstructive Jaundice Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000010968 computed tomography angiography Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238461P | 2015-10-07 | 2015-10-07 | |
| US62/238,461 | 2015-10-07 | ||
| PCT/US2016/055988 WO2017062765A1 (en) | 2015-10-07 | 2016-10-07 | Methods of treating injuries or conditions related to cns edema |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021022562A Division JP2021073317A (ja) | 2015-10-07 | 2021-02-16 | Ｃｎｓ浮腫に関連する損傷または状態を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018530564A JP2018530564A (ja) | 2018-10-18 |
| JP2018530564A5 true JP2018530564A5 (https=) | 2019-11-14 |
| JP7349786B2 JP7349786B2 (ja) | 2023-09-25 |
Family
ID=58488580
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517841A Active JP7349786B2 (ja) | 2015-10-07 | 2016-10-07 | Ｃｎｓ浮腫に関連する損傷または状態を処置する方法 |
| JP2021022562A Withdrawn JP2021073317A (ja) | 2015-10-07 | 2021-02-16 | Ｃｎｓ浮腫に関連する損傷または状態を処置する方法 |
| JP2023020327A Active JP7592768B2 (ja) | 2015-10-07 | 2023-02-13 | Ｃｎｓ浮腫に関連する損傷または状態を処置する方法 |
| JP2024142687A Active JP7810762B2 (ja) | 2015-10-07 | 2024-08-23 | Ｃｎｓ浮腫に関連する損傷または状態を処置する方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021022562A Withdrawn JP2021073317A (ja) | 2015-10-07 | 2021-02-16 | Ｃｎｓ浮腫に関連する損傷または状態を処置する方法 |
| JP2023020327A Active JP7592768B2 (ja) | 2015-10-07 | 2023-02-13 | Ｃｎｓ浮腫に関連する損傷または状態を処置する方法 |
| JP2024142687A Active JP7810762B2 (ja) | 2015-10-07 | 2024-08-23 | Ｃｎｓ浮腫に関連する損傷または状態を処置する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20180280325A1 (https=) |
| EP (1) | EP3359162B1 (https=) |
| JP (4) | JP7349786B2 (https=) |
| KR (2) | KR102681027B1 (https=) |
| CN (2) | CN108348534A (https=) |
| AU (3) | AU2016335767B2 (https=) |
| BR (1) | BR112018006925A2 (https=) |
| CA (1) | CA3001321A1 (https=) |
| EA (1) | EA201890893A1 (https=) |
| ES (1) | ES2940669T3 (https=) |
| HK (1) | HK1257542A1 (https=) |
| IL (1) | IL258509B2 (https=) |
| MA (1) | MA45574A (https=) |
| MX (1) | MX392466B (https=) |
| WO (1) | WO2017062765A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6238969B2 (ja) | 2012-05-08 | 2017-11-29 | エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． | 新規方法 |
| WO2015069956A2 (en) | 2013-11-06 | 2015-05-14 | Aeromics, Llc | Novel formulations |
| CA3001321A1 (en) * | 2015-10-07 | 2017-04-13 | Biogen Chesapeake Llc | Methods of treating injuries or conditions related to cns edema |
| WO2020041905A1 (en) * | 2018-08-31 | 2020-03-05 | The University Of British Columbia | Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds |
| MA55813A (fr) * | 2019-05-02 | 2022-03-09 | Biogen Chesapeake Llc | Procédé de traitement de sujets souffrant de contusions du système nerveux central |
| CN120004770A (zh) * | 2020-07-17 | 2025-05-16 | 上海森辉医药有限公司 | 磺酰脲类衍生物及其医药用途 |
| US12251389B1 (en) * | 2024-04-22 | 2025-03-18 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
| WO2025212155A1 (en) * | 2024-04-05 | 2025-10-09 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor |
| US12251388B1 (en) | 2024-05-09 | 2025-03-18 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
| WO2025212189A1 (en) * | 2024-04-05 | 2025-10-09 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema using a sur1-trpm4 channel inhibitor |
| WO2025212154A1 (en) * | 2024-04-05 | 2025-10-09 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856360A (en) | 1996-05-03 | 1999-01-05 | Children's Hospital Medical Center | Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock |
| US8980952B2 (en) * | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
| EP2438913B1 (en) | 2002-03-20 | 2020-05-06 | University of Maryland, Baltimore | A non-selective cation channel in neural cells and compounds that block the channel for use in treating brain swelling |
| US20050246000A1 (en) * | 2004-05-03 | 2005-11-03 | Seacoast Technologies, Inc. | Cooled craniectomy |
| WO2009002832A2 (en) | 2007-06-22 | 2008-12-31 | University Of Maryland, Baltimore | Inhibitors of ncca-atp channels for therapy |
| PT2868315T (pt) * | 2007-12-04 | 2017-09-04 | Remedy Pharmaceuticals Inc | Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos |
| EP3339190A1 (en) * | 2010-07-19 | 2018-06-27 | Biogen Chesapeake LLC | Containers for glyburide solutions |
| CA3001321A1 (en) * | 2015-10-07 | 2017-04-13 | Biogen Chesapeake Llc | Methods of treating injuries or conditions related to cns edema |
-
2016
- 2016-10-07 CA CA3001321A patent/CA3001321A1/en active Pending
- 2016-10-07 MA MA045574A patent/MA45574A/fr unknown
- 2016-10-07 CN CN201680066630.6A patent/CN108348534A/zh active Pending
- 2016-10-07 KR KR1020187012950A patent/KR102681027B1/ko active Active
- 2016-10-07 EA EA201890893A patent/EA201890893A1/ru unknown
- 2016-10-07 HK HK18116503.6A patent/HK1257542A1/zh unknown
- 2016-10-07 KR KR1020247021781A patent/KR20240105519A/ko not_active Ceased
- 2016-10-07 US US15/763,932 patent/US20180280325A1/en not_active Abandoned
- 2016-10-07 ES ES16854422T patent/ES2940669T3/es active Active
- 2016-10-07 CN CN202211412393.8A patent/CN115737816A/zh active Pending
- 2016-10-07 AU AU2016335767A patent/AU2016335767B2/en active Active
- 2016-10-07 WO PCT/US2016/055988 patent/WO2017062765A1/en not_active Ceased
- 2016-10-07 EP EP16854422.9A patent/EP3359162B1/en active Active
- 2016-10-07 JP JP2018517841A patent/JP7349786B2/ja active Active
- 2016-10-07 BR BR112018006925A patent/BR112018006925A2/pt not_active Application Discontinuation
- 2016-10-07 MX MX2018004286A patent/MX392466B/es unknown
- 2016-10-07 IL IL258509A patent/IL258509B2/en unknown
-
2021
- 2021-02-16 JP JP2021022562A patent/JP2021073317A/ja not_active Withdrawn
- 2021-09-29 US US17/488,591 patent/US11951085B2/en active Active
-
2022
- 2022-11-28 AU AU2022279369A patent/AU2022279369B2/en active Active
-
2023
- 2023-02-13 JP JP2023020327A patent/JP7592768B2/ja active Active
-
2024
- 2024-03-04 US US18/595,205 patent/US20240216309A1/en active Pending
- 2024-08-23 JP JP2024142687A patent/JP7810762B2/ja active Active
- 2024-09-30 US US18/902,504 patent/US20250017880A1/en active Pending
-
2025
- 2025-04-14 AU AU2025202620A patent/AU2025202620A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530564A5 (https=) | ||
| Elliott et al. | Comparison of balloon angioplasty and papaverine infusion for the treatment of vasospasm following aneurysmal subarachnoid hemorrhage | |
| JP7592768B2 (ja) | Ｃｎｓ浮腫に関連する損傷または状態を処置する方法 | |
| Liotta | Management of cerebral edema, brain compression, and intracranial pressure | |
| Cascino | Generalized convulsive status epilepticus | |
| Fang et al. | Microangiopathy in diabetic polyneuropathy revisited. | |
| Fulgham et al. | Management of acute ischemic stroke | |
| Rabinstein et al. | Rapidly progressive dementia due to bilateral internal carotid artery occlusion with infarction of the total length of the corpus callosum | |
| Bertram et al. | Acute and cricital care in neurology | |
| Pellegrini et al. | Hitting a wall: an ambiguous case of Wallenberg syndrome | |
| JP5509085B2 (ja) | 血栓溶解についての新規な患者亜群 | |
| CN107998115B (zh) | 一种延长脑梗死溶栓时间窗的药物和方法 | |
| Larson Jr et al. | Maternally administered esmolol decreases fetal as well as maternal heart rate | |
| Wittstock et al. | Transient third-degree atrioventricular block following rapid lacosamide titration in a patient with nonconvulsive status epilepticus | |
| Wartenberg et al. | Management of large hemispheric infarction | |
| Wong et al. | Acute ischaemic stroke: management, recent advances and controversies | |
| JP2011500617A5 (https=) | ||
| Grazer | Chewing nifedipine to rapidly treat hypertension: Haft JI, Litterer WE Arch Intern Med 144: 2357–2359 Dec 1984 | |
| Schellinger | Stroke management in the early phase | |
| Pourmand | Status Epilepticus | |
| Elliott et al. | Comparison of balloon angioplasty and papaverine infusion for the treatment of vasospasm following aneurysmal subarachnoid hemorrhage | |
| JP2008230968A (ja) | 脳梗塞治療用の医薬 |